Our scientists have recently tested a combination of immunotherapy and radiotherapy as a method to stop treatment resistance. Their work, in mice with breast skin and bowel cancers, showed that the combined approach improved survival and prevented disease recurrence.
Manchester researchers have found that breast cells can reawaken and continue to grow following treatment. Their discovery has implications for the design of breast cancer therapies.
Studies into basic cancer cell biology and the development of clinical sample testing will be boosted by the award of £24 million to The University of Manchester from the Medical Research Council. The funding will allow the creation of a Clinical Proteomics Centre and the Manchester Single Cell Research Centre.